• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Diligent Announces Market Insights Reporting Powered by S&P Global Market Intelligence, Giving Directors and Executives Unrivaled Financial and Risk Insights

    1/15/25 9:00:00 AM ET
    $MYGN
    $YEXT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    EDP Services
    Technology
    Get the next $MYGN alert in real time by email

    New reports bring key financial insights and market comparisons to directors, CFOs, general counsel and executives, giving clarity into investor risks.

    Diligent, a leading GRC SaaS company, today announced it is collaborating with S&P Global's Market Intelligence division to launch Diligent Market Insights Reporting. Powered by S&P Capital IQ Pro data, the reports give corporate directors and executives timely, contextualized insights into global financial data and peer performance – including market sentiment, analyst consensus, peer developments and industry analysis – to stay ahead of market and investor risks. The reports are built within the Diligent One Platform, Diligent's leading GRC platform empowering more than 1 million users and 700,000 board members and leaders to make better decisions.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250115272711/en/

    (Graphic: Business Wire)

    (Graphic: Business Wire)

    "Today's corporate directors are navigating an increasingly complex and fast-moving risk landscape," said Mark Davis, Board Director at Yext (NYSE:YEXT) and Myriad Genetics (NASDAQ:MYGN), former National Audit Leader of Deloitte Private and Greater Tri-state IPO Services Leader. "Staying ahead of these dynamics requires more than traditional reporting—it demands timely, contextualized insights that empower leaders to anticipate risks and seize opportunities. Boards need tools that bridge the gap between raw data and actionable insights to drive informed, strategic decisions."

    In today's fast-paced business landscape, public company boards and executives need timely and relevant financial data to make informed decisions. Diligent Market Insights Reporting integrates S&P Global Market Intelligence's unparalleled financial data with Diligent Boards to deliver industry expert designed reports of a company's market position, directly to boards and leadership. This integration allows for a more streamlined and curated delivery of data so leadership can gain clarity into investor risks.

    Key benefits of Diligent Market Insights Reporting powered by S&P Capital IQ Pro data include:

    • Access to the latest comprehensive market data including peer comparisons, stock charts, key developments, market analysis, analyst price targets, recommendations, and earnings sentiment analysis.
    • Tailored insights for corporate directors, CFOs, GCs and CEOs, delivered securely and in a familiar and consistent format, in the world's leading board portal.
    • Enhanced decision making, empowering executive leaders with the tools to deliver the right insights and context to the board, enhancing their ability to make strategic decisions.
    • Seamless integration to Diligent Boards, enabling CFOs, finance and investor relations teams to easily pull data from a single source, provide commentary on key developments and share with stakeholders.

    Through the Diligent One Platform, customers can also gain access to other board reporting integrations to streamline data collection, break down silos and surface clear insights built on reliable, up-to-date data.

    "This collaboration with S&P Global Market Intelligence underscores our commitment to delivering actionable and reliable market insights to our customers," said Brian Stafford, President and CEO of Diligent. "Market Insights Reporting will elevate how boards and executives access and utilize financial data, ensuring they are always prepared to make informed decisions that drive their organizations forward."

    "We are excited to work with Diligent on this innovative capability," said Warren Breakstone, Global Head of Data & Research at S&P Global Market Intelligence. "By integrating our financial insights with Diligent's governance technology, we are assisting boards and executives to navigate the complexities of today's financial landscape with greater confidence and clarity."

    For more information on Market Insights Reporting powered by S&P Global Market Intelligence, visit: https://www.diligent.com/lp/market-insights-reporting

    About Diligent

    Diligent is the leading GRC SaaS company, empowering more than 1 million users and 700,000 board members and leaders to make better decisions, faster. The Diligent One Platform helps organizations connect their entire GRC practice — including governance, risk, compliance, audit and ESG — to bring clarity to complex risk, stay ahead of regulatory changes and deliver impactful insights, in one consolidated view. Learn more at diligent.com.

    Follow Diligent on LinkedIn, X (Twitter) and Facebook.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250115272711/en/

    Media Contact

    Julia Stoyanov

    Communications Director, Diligent

    +1 (604) 669-4225

    [email protected]

    Get the next $MYGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MYGN
    $YEXT

    CompanyDatePrice TargetRatingAnalyst
    Myriad Genetics Inc.
    $MYGN
    5/8/2025Outperform → Peer Perform
    Wolfe Research
    Myriad Genetics Inc.
    $MYGN
    5/7/2025$6.00Overweight → Equal Weight
    Wells Fargo
    Myriad Genetics Inc.
    $MYGN
    4/9/2025Buy → Neutral
    Guggenheim
    Myriad Genetics Inc.
    $MYGN
    3/12/2025$11.50 → $12.50Neutral → Overweight
    Piper Sandler
    Myriad Genetics Inc.
    $MYGN
    2/12/2025$29.00Buy
    Craig Hallum
    Myriad Genetics Inc.
    $MYGN
    12/10/2024$18.00Neutral
    UBS
    Myriad Genetics Inc.
    $MYGN
    12/9/2024$30.00 → $21.00Outperform → Market Perform
    Leerink Partners
    Myriad Genetics Inc.
    $MYGN
    9/19/2024$32.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $MYGN
    $YEXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Waugh Seth H. bought $216,647 worth of shares (32,600 units at $6.65), increasing direct ownership by 27% to 153,350 units (SEC Form 4)

      4 - Yext, Inc. (0001614178) (Issuer)

      9/19/24 4:56:10 PM ET
      $YEXT
      EDP Services
      Technology

    $MYGN
    $YEXT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

      SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) --  Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology published a real-world study suggesting that the results of RiskScore® led clinicians to recommend breast cancer screening aligned with patients' individual risk. RiskScore, Myriad's clinically validated breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test, combines a polygenic risk score (PRS) validated for all ancestries with the widely-used Tyrer-Cuzick model to predict five-year and remaining lifetime risk of breast cancer. The study, "Association of Polygenic

      5/7/25 4:30:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

      Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. MyRisk®testing volume in the affected population grew 11% year-over-year. First quarter 2025 gross margin of 69% increased 40 basis points year-over-year, benefiting from greater laboratory efficiencies. First quarter 2025 GAAP net loss of $0.1 million, or $0.00 EPS, driven by $29 million tax benefit. Adjusted EPS was $(0.03) in the first quarter 2025.

      5/6/25 4:05:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

      SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet concerns about potential side effects remain a significant barrier, preventing more than half (52%) from taking medication, according to the latest GeneSight® Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine. The majority of these patients (54%) agree that genetic testing for mental health medications (known as pharmacogenomic or PGx testing) could reduce these concerns. "It's encouraging to

      4/30/25 8:00:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    $YEXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Myriad Genetics Inc.

      SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)

      11/14/24 4:16:31 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Yext Inc.

      SC 13G/A - Yext, Inc. (0001614178) (Subject)

      11/14/24 4:02:14 PM ET
      $YEXT
      EDP Services
      Technology
    • SEC Form SC 13G filed by Myriad Genetics Inc.

      SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)

      5/1/24 4:21:33 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    $YEXT
    Financials

    Live finance-specific insights

    See more
    • Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

      Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. MyRisk®testing volume in the affected population grew 11% year-over-year. First quarter 2025 gross margin of 69% increased 40 basis points year-over-year, benefiting from greater laboratory efficiencies. First quarter 2025 GAAP net loss of $0.1 million, or $0.00 EPS, driven by $29 million tax benefit. Adjusted EPS was $(0.03) in the first quarter 2025.

      5/6/25 4:05:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

      SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2025 earnings conference call at 4:30 pm EDT on Tuesday, May 6, 2025. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the first quarter 2025. A live webcast of the conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon register

      4/29/25 9:00:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Yext Announces Fourth Quarter Fiscal 2025 Results

      Q4 Revenue of $113.1 million, up 12% year-over-year, driven by the integration of Hearsay Systems FY25 Revenue of $421.0 million, up 4% year-over-year Q4 Net Loss Per Share, basic, of $0.06 or non-GAAP Earnings Per Share of $0.13 Q4 Adjusted EBITDA of $24.6 million, resulting in an adjusted EBITDA margin of 22% ARR, including usage, of $442.7 million Introduced FY26 outlook of adjusted EBITDA in the range of $100.0 million to $103.0 million Share repurchase authorization increased by $50.0 million Yext, Inc. (NYSE:YEXT), the leading digital presence platform for multi-location brands, today announced its results for the three months ended January 31, 2025, or Yext's fourth qu

      3/5/25 4:05:00 PM ET
      $YEXT
      EDP Services
      Technology

    $MYGN
    $YEXT
    Leadership Updates

    Live Leadership Updates

    See more
    • Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

      SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&Ls, and driving growth through innovative go-to-market strategies. "Brian brings a unique combination of strategic vision and operational excellence, combined with a passion for patient-centric

      4/7/25 8:00:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Specright Announces Appointment of Mike Boese as CEO; Founder Matthew Wright Transitions to Executive Chairman

      Leadership changes address surge in Specification Data Management platform demand and utilization and prepare Specright for the next stage of growth. Specright, the leader in Specification Management software, today announced the appointment of Mike Boese as its new CEO, effective immediately, to accelerate the company's next stage of growth. Boese will lead execution of Specright's strategic vision of helping companies digitize and harness the power of specification data across supply chains to reduce costs, accelerate product and packaging development, and drive sustainability. Boese's priorities at Specright will include scaling customer operations, driving product innovation, and build

      4/2/25 12:00:00 PM ET
      $YEXT
      EDP Services
      Technology
    • Myriad Genetics Announces Senior Leadership Transition

      SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors has appointed Sam Raha, the Company's current Chief Operating Officer (COO), as President and Chief Executive Officer (CEO) and as a member of the Board, effective April 30, 2025. Mr. Raha will replace Paul J. Diaz, who is stepping down to join private equity firm Cressey & Company as a Managing Partner. Mr. Diaz will continue to serve the Company as a consultant to Mr. Raha and the Board of Directors for another year. "Since joining Myriad in December 2023, Sam has played an integral role in sh

      2/24/25 4:05:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    $YEXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commerical Officer Donnelly Brian J was granted 397,534 shares (SEC Form 4)

      4 - MYRIAD GENETICS INC (0000899923) (Issuer)

      5/2/25 4:15:16 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Donnelly Brian J

      3 - MYRIAD GENETICS INC (0000899923) (Issuer)

      5/1/25 4:29:48 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Verratti Mark

      4 - MYRIAD GENETICS INC (0000899923) (Issuer)

      5/1/25 4:27:14 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    $YEXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Myriad Genetics downgraded by Wolfe Research

      Wolfe Research downgraded Myriad Genetics from Outperform to Peer Perform

      5/8/25 8:27:12 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Myriad Genetics from Overweight to Equal Weight and set a new price target of $6.00

      5/7/25 8:36:31 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics downgraded by Guggenheim

      Guggenheim downgraded Myriad Genetics from Buy to Neutral

      4/9/25 8:36:07 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    $YEXT
    SEC Filings

    See more
    • SEC Form 10-Q filed by Myriad Genetics Inc.

      10-Q - MYRIAD GENETICS INC (0000899923) (Filer)

      5/6/25 8:48:53 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MYRIAD GENETICS INC (0000899923) (Filer)

      5/6/25 4:08:36 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-8 filed by Myriad Genetics Inc.

      S-8 - MYRIAD GENETICS INC (0000899923) (Filer)

      5/1/25 4:03:06 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care